Multimodality approaches for pancreatic cancer

Gary Y. Yang; Timothy D. Wagner; Martin Fuss; Charles R. Thomas

doi:10.3322/canjclin.55.6.352

Multimodality approaches for pancreatic cancer

Gary Y. Yang, Timothy D. Wagner, Martin Fuss, Charles R. Thomas

Research output: Contribution to journal › Article › peer-review

Abstract

The role of combined-modality therapy for pancreatic cancer is evolving with the recent development and completion of major, multi-institutional clinical trials. One of the challenges for the busy clinician is to appreciate the variation in staging, surgical expertise, and application of either definitive chemoradiotherapy or adjuvant chemoradiotherapy for local and/or regionally advanced disease. Our aim is to summarize the current state-of-the-art management and future directions regarding the multimodality approach to pancreatic cancer. © American Cancer Society, Inc., 2005.

Original language	American English
Pages (from-to)	352-367
Number of pages	16
Journal	Ca-A Cancer Journal for Clinicians
Volume	55
Issue number	6
DOIs	https://doi.org/10.3322/canjclin.55.6.352
State	Published - Nov 2005
Externally published	Yes

ASJC Scopus Subject Areas

Hematology
Oncology

Keywords

Diagnostic Imaging/methods
Pancreatic Neoplasms/diagnosis
Humans
Immunotherapy
Angiogenesis Inhibitors/therapeutic use
Matrix Metalloproteinase Inhibitors
ErbB Receptors/antagonists & inhibitors
Combined Modality Therapy/trends

Disciplines

Medicine and Health Sciences
Pathology

Access to Document

10.3322/canjclin.55.6.352License: Unspecified

OpenUrl availability

Full text

Cite this

@article{2d2d713e2f0e4fcf94891b47efd78880,

title = "Multimodality approaches for pancreatic cancer",

abstract = "The role of combined-modality therapy for pancreatic cancer is evolving with the recent development and completion of major, multi-institutional clinical trials. One of the challenges for the busy clinician is to appreciate the variation in staging, surgical expertise, and application of either definitive chemoradiotherapy or adjuvant chemoradiotherapy for local and/or regionally advanced disease. Our aim is to summarize the current state-of-the-art management and future directions regarding the multimodality approach to pancreatic cancer. {\textcopyright} American Cancer Society, Inc., 2005.",

keywords = "Diagnostic Imaging/methods, Pancreatic Neoplasms/diagnosis, Humans, Immunotherapy, Angiogenesis Inhibitors/therapeutic use, Matrix Metalloproteinase Inhibitors, ErbB Receptors/antagonists & inhibitors, Combined Modality Therapy/trends",

author = "Yang, {Gary Y.} and Wagner, {Timothy D.} and Martin Fuss and Thomas, {Charles R.}",

note = "CA Cancer J Clin. 2005 Nov-Dec;55(6):352-67. Review",

year = "2005",

month = nov,

doi = "10.3322/canjclin.55.6.352",

language = "American English",

volume = "55",

pages = "352--367",

journal = "Ca-A Cancer Journal for Clinicians",

issn = "0007-9235",

number = "6",

}

TY - JOUR

T1 - Multimodality approaches for pancreatic cancer

AU - Yang, Gary Y.

AU - Wagner, Timothy D.

AU - Fuss, Martin

AU - Thomas, Charles R.

N1 - CA Cancer J Clin. 2005 Nov-Dec;55(6):352-67. Review

PY - 2005/11

Y1 - 2005/11

N2 - The role of combined-modality therapy for pancreatic cancer is evolving with the recent development and completion of major, multi-institutional clinical trials. One of the challenges for the busy clinician is to appreciate the variation in staging, surgical expertise, and application of either definitive chemoradiotherapy or adjuvant chemoradiotherapy for local and/or regionally advanced disease. Our aim is to summarize the current state-of-the-art management and future directions regarding the multimodality approach to pancreatic cancer. © American Cancer Society, Inc., 2005.

AB - The role of combined-modality therapy for pancreatic cancer is evolving with the recent development and completion of major, multi-institutional clinical trials. One of the challenges for the busy clinician is to appreciate the variation in staging, surgical expertise, and application of either definitive chemoradiotherapy or adjuvant chemoradiotherapy for local and/or regionally advanced disease. Our aim is to summarize the current state-of-the-art management and future directions regarding the multimodality approach to pancreatic cancer. © American Cancer Society, Inc., 2005.

KW - Diagnostic Imaging/methods

KW - Pancreatic Neoplasms/diagnosis

KW - Humans

KW - Immunotherapy

KW - Angiogenesis Inhibitors/therapeutic use

KW - Matrix Metalloproteinase Inhibitors

KW - ErbB Receptors/antagonists & inhibitors

KW - Combined Modality Therapy/trends

UR - https://www.ncbi.nlm.nih.gov/pubmed/16282280

UR - https://www.mendeley.com/catalogue/96fb2793-055e-3713-a0ba-6cc13a36a4c2/

U2 - 10.3322/canjclin.55.6.352

DO - 10.3322/canjclin.55.6.352

M3 - Article

C2 - 16282280

SN - 0007-9235

VL - 55

SP - 352

EP - 367

JO - Ca-A Cancer Journal for Clinicians

JF - Ca-A Cancer Journal for Clinicians

IS - 6

ER -

Multimodality approaches for pancreatic cancer

Abstract

ASJC Scopus Subject Areas

Keywords

Disciplines

Access to Document

OpenUrl availability

Other files and links

Cite this